DELRAY BEACH, Fla., March 22, 2019 (GLOBE NEWSWIRE) -- Exactus Inc. (OTCQB:EXDI / OTCQB:EXDID), a healthcare company pursuing opportunities in Hemp derived, Cannabidiol (CBD) products applauds CVS’s decision announced yesterday to begin selling CBD (cannabidiol) products in select stores throughout the country.
Exactus believes that the best way for patients and their physicians to feel confident in their choice of CBD products is to purchase them from a trusted name with a proven track record. There are many choices in the marketplace for CBD products, and it can be confusing for most consumers that are new to using CBD.
Philip J Young, CEO, stated, “Our driving mission and philosophy at Exactus is to farm, process and manufacture quality products. With the quality built into every product and tested to confirm that the potency, purity, and content that is on the label is indeed, exactly what is in the product. We are happy to see a national icon such as CVS make a statement and begin selling CBD. This is a trend that is sure to grow, and we believe we can take a leadership position in.”
Exactus recently announced that it had placed its first million-dollar product request from its partner and largest shareholder Ceed2Med. The availability of the tinctures, gel caps and topical lotions puts the company in a strong position in the market place. In addition, the availability of the remaining amount of the annual 2,500-kilogram product guarantee combined with the recently announced Exactus One World, 200 acre, Oregon farm ensures Exactus the quantity and capability sufficient to ensure product availability through 2020.
For information about Exactus’ products and availability, please call 804-205-5036 or email cbd@exactusinc.com.
About Exactus:
Exactus, Inc., is a healthcare company pursuing opportunities in two distinct business segments. The company is engaged in producing industrial hemp from farms in Oregon and plans to extract and manufacture directly through cGMP facilities. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3% or less. That amount has not been shown to make a person feel "high." THC is the psychoactive compound found in cannabis. The Company also has been pursuing businesses in point of care diagnostics.
